Orticumab recognizes and specifically binds a specific epitope of oxLDL. Binding of oxLDL by orticumab not only has the potential to directly reduce cytotoxic and atherosclerotic effects of oxLDL by leading to it sequestration and increased clearance. The immune complex formed by orticumab and oxLDL has also been demonstrated to reduce inflammation by inhibiting macrophage activation in atherosclerotic plaques. Both activities of orticumab have the potential to reduce atherosclerotic plaque burden and prevent major cardiovascular events, such as acute coronary syndrome and heart attack.